ResMed Inc

ResMed Inc Stock Forecast & Price Prediction

Live ResMed Inc Stock (RMD) Price
$245.63

10

Ratings

  • Buy 4
  • Hold 2
  • Sell 4
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$245.63

P/E Ratio

32.58

Volume Traded Today

$802,500

Dividend

$0.53

52 Week High/low

260.49/140.81

ResMed Inc Market Cap

$36.06B

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $RMD ๐Ÿ›‘

Before you buy RMD you'll want to see this list of ten stocks that have huge potential. Want to see if RMD made the cut? Enter your email below

RMD Summary

Based on ratings from 10 stock analysts, the ResMed Inc stock price is expected to increase by 1.66% in 12 months. This is calculated by using the average 12-month stock price forecast for ResMed Inc. The lowest target is $190 and the highest is $283. Please note analyst price targets are not guaranteed and could be missed completely.

RMD Analyst Ratings

About 10 Wall Street analysts have assigned RMD 4 buy ratings, 2 hold ratings, and 4 sell ratings. This means that analysts expect ResMed Inc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on RMD. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

RMD stock forecast by analyst

These are the latest 20 analyst ratings of RMD.

Analyst/Firm

Rating

Price Target

Change

Date

Brett Fishbin
Keybanc

Overweight

$266

Maintains

Oct 25, 2024
Joe Vruwink
Baird

Outperform

$283

Maintains

Oct 25, 2024
Craig Wong-Pan
RBC Capital

Sector Perform

$232

Maintains

Oct 25, 2024
Mike Matson
Needham

Hold


Reiterates

Oct 25, 2024
Craig Wong-Pan
RBC Capital

Sector Perform

$224

Maintains

Oct 1, 2024
Mike Matson
Needham

Hold


Reiterates

Oct 1, 2024
Lyanne Harrison
B of A Securities

Buy

$270

Maintains

Sep 26, 2024
Joe Vruwink
Baird

Outperform

$280

Initiates

Sep 24, 2024
Mike Matson
Needham

Hold


Reiterates

Sep 18, 2024
Mike Polark
Wolfe Research

Underperform

$180

Downgrade

Sep 18, 2024
Mike Matson
Needham

Hold

$236

Downgrade

Sep 4, 2024
Mike Matson
Needham

Buy

$236

Reiterates

Aug 2, 2024
Craig Wong-Pan
RBC Capital

Sector Perform

$206

Maintains

Aug 2, 2024
Brett Fishbin
Keybanc

Overweight

$251

Maintains

Aug 2, 2024
Craig Wong-Pan
RBC Capital

Sector Perform

$204

Maintains

Jul 23, 2024
Suraj Kalia
Oppenheimer

Perform


Downgrade

Jun 25, 2024
Mike Matson
Needham

Buy

$236

Reiterates

Jun 24, 2024
Mathieu Chevrier
Citigroup

Neutral


Downgrade

Jun 24, 2024
Brett Fishbin
Keybanc

Overweight

$238

Maintains

Apr 26, 2024
Suraj Kalia
Oppenheimer

Outperform

$200

Maintains

Apr 26, 2024

RMD Company Information

What They Do: Develops medical devices and cloud-based software.

Business Model: The company operates through two segments: Sleep and Respiratory Care, and Software as a Service. It generates revenue by selling a variety of medical devices for respiratory disorders, along with cloud-based applications that provide remote monitoring and management of patient care, enhancing patient engagement and compliance.

Other Information: Founded in 1989 and headquartered in San Diego, California, the company serves markets including sleep clinics and home healthcare through a robust distribution network. Their innovative solutions, such as AirView and myAir, highlight the company's focus on integrating technology with healthcare to improve patient outcomes.
RMD
ResMed Inc (RMD)

When did it IPO

1995

Staff Count

9,980

Country

United States

Sector/Industry

Healthcare/Medical Instruments & Supplies

CEO

Mr. Michael J. Farrell BE, MBA, SM

Market Cap

$36.06B

ResMed Inc (RMD) Financial Data

In 2023, RMD generated $4.22B in revenue, which was a increase of 18.02% from the previous year. This can be seen as a signal that RMD's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

$3.20B

0.00 %
From Previous Year

Revenue From 2022

$3.58B

11.93 %
From Previous Year

Revenue From 2023

$4.22B

18.02 %
From Previous Year
  • Revenue TTM $4.81B
  • Operating Margin TTM 31.6%
  • Gross profit TTM $2.66B
  • Return on assets TTM 13.3%
  • Return on equity TTM 23.6%
  • Profit Margin 23.1%
  • Book Value Per Share 35.39%
  • Market capitalisation $36.06B
  • Revenue for 2021 $3.20B
  • Revenue for 2022 $3.58B
  • Revenue for 2023 $4.22B
  • EPS this year (TTM) $7.54

ResMed Inc (RMD) Latest News

News Image

Tue, 05 Nov 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - ResMed's CEO Mick Farrell and CMO Dr. Carlos Nunez will speak at the UBS Global Healthcare Conference on November 12, 2024, at 3:30 PM PST in Rancho Palos Verdes, CA.

Why It Matters - The participation of ResMed's CEO and CMO in a major healthcare conference highlights the company's visibility and potential growth opportunities, influencing investor sentiment and stock performance.

News Image

Mon, 04 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - Zacks Premium research service offers Zacks Style Scores, facilitating stock selection for value, growth, and momentum investors.

Why It Matters - Zacks Style Scores enhance stock selection by identifying strong candidates across investment strategies, potentially leading to better returns and informed investment decisions.

News Image

Mon, 04 Nov 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - ResMed (RMD) shows strong growth potential, indicating it may outperform the market.

Why It Matters - ResMed's strong growth attributes suggest potential for higher returns, indicating it may outperform competitors, attracting investor interest and possibly boosting stock performance.

News Image

Sun, 03 Nov 2024

Sentiment - POSITIVE

Source - Seeking Alpha

Summary - The SPDR S&P 500 ETF Trust fell 0.89% in October. Top 15 dividend growth stocks for November 2024 show a 1.24% yield and are 23% undervalued, with an 11.33% CAGR since September 2020.

Why It Matters - The SPDR S&P 500 ETF's October loss signals potential market volatility, while undervalued dividend stocks may attract income-focused investors seeking growth amid uncertainty.

News Image

Tue, 29 Oct 2024

Sentiment - POSITIVE

Source - Schwab Network

Summary - ResMed (RMD) CEO Mick Farrell announced the company exceeded earnings expectations, focusing on treatments for sleep apnea and COPD.

Why It Matters - ResMed's earnings beat indicates strong demand and effective management, signaling potential growth and profitability, which could positively influence stock performance.

News Image

Mon, 28 Oct 2024

Sentiment - POSITIVE

Source - Zacks Investment Research

Summary - ResMed (RMD) has reached a 52-week high. Investors may look into the company's fundamentals for insights on potential future gains.

Why It Matters - ResMed's 52-week high signals strong market performance, but analyzing its fundamentals will reveal potential for continued growth or risks, influencing investment decisions.

...

RMD Frequently asked questions

The highest forecasted price for RMD is $283 from Joe Vruwink at Baird.

The lowest forecasted price for RMD is $190 from from

The RMD analyst ratings consensus are 4 buy ratings, 2 hold ratings, and 4 sell ratings.